# Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

Study · id `cardio:ct-nct06501651` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06501651](<https://clinicaltrials.gov/study/NCT06501651>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06501651

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 297 participants.

## Technical summary

Registry record NCT06501651. Randomized; no masking; primary purpose treatment. Start 2024-08-01 (anticipated); primary completion 2025-04-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 297 participants (planned count; ClinicalTrials.gov record NCT06501651, source copy `cardio:ctgov-nct06501651-2024-07-15`, retrieved 2026-10-26)
- Planned start: 2024-08-01 (anticipated) (ClinicalTrials.gov record NCT06501651, source copy `cardio:ctgov-nct06501651-2024-07-15`, retrieved 2026-10-26)
- Primary completion: 2025-04-10 (anticipated) (ClinicalTrials.gov record NCT06501651, source copy `cardio:ctgov-nct06501651-2024-07-15`, retrieved 2026-10-26)
- Completion: 2025-04-10 (anticipated) (ClinicalTrials.gov record NCT06501651, source copy `cardio:ctgov-nct06501651-2024-07-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06501651, source copy `cardio:ctgov-nct06501651-2024-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06501651-2024-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
- Acronym: Hyper-Save
- Condition: Essential Hypertension
- Condition: Type 2 Diabetes
- Condition: Nephropathy
- Intervention (Drug): Sacubitril/Valsartan
- Intervention (Drug): Valsartan
- Lead sponsor: Sichuan Academy of Medical Sciences
- Lead sponsor class: OTHER
- Collaborator: The Second Affiliated Hospital of Chongqing Medical University
- Collaborator class: OTHER
- Collaborator: Nanchong Central Hospital
- Collaborator class: OTHER\_GOV
- Collaborator: The People's Hospital of Leshan
- Collaborator class: OTHER
- Collaborator: The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University
- Collaborator class: UNKNOWN
- Collaborator: Chengdu First People's Hospital
- Collaborator class: OTHER
- Collaborator: Mianyang People's Hospital
- Collaborator class: UNKNOWN
- Collaborator: Guang'an people's hospital of Sichuan province
- Collaborator class: OTHER
- Collaborator: Meishan Traditional Chinese Medicine Hospital
- Collaborator class: OTHER
- Collaborator: Qijiang District People's Hospital
- Collaborator class: UNKNOWN
- Collaborator: Meishan People's Hospital
- Collaborator class: UNKNOWN
- Collaborator: The First People's Hospital of Guangyuan
- Collaborator class: UNKNOWN
- Collaborator: Dazhou Central Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Sichuan Academy of Medical Sciences (`cardio:org-sichuan-academy-of-medical-sciences`)
- Registry lists this organization as a collaborator: The Second Affiliated Hospital of Chongqing Medical University (`cardio:org-the-second-affiliated-hospital-of-chongqing-medical-739711`)

## Provenance

Content hash: e9153dd2f02bc249f4868e59e963a8544f871e373a5df0b36963fb2d032b8527
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
